Pancreatic Cancer Research

ResearcherUniversitätsmedizin RostockActive in the last 2 years

Robert Jaster

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8220-4570; OpenAlex author ID A5019793360. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers

Papers 9

  1. Effects of triggers of senescence and senolysis in murine pancreatic cancer cells. Last author DOI 10.1016/j.hbpd.2024.06.001↗
  2. Evidence-Based Severity Assessment of Animal Models for Pancreatic Cancer. Co-author DOI 10.3390/biomedicines12071494↗
  3. Uncoupling protein 2 deficiency of non-cancerous tissues inhibits the progression of pancreatic cancer in mice. Last author DOI 10.1016/j.hbpd.2022.12.003↗
  4. Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines. Co-author DOI 10.3390/cancers14184467↗
  5. Towards biomarkers for outcomes after pancreatic ductal adenocarcinoma and ischaemic stroke, with focus on (co)-morbidity and ageing/cellular senescence (SASKi… Co-author DOI 10.1136/bmjopen-2020-039560↗
  6. Blocking Autophagy in Cancer-Associated Fibroblasts Supports Chemotherapy of Pancreatic Cancer Cells. Co-author DOI 10.3389/fonc.2018.00590↗
  7. Mathematical modelling unravels regulatory mechanisms of interferon-γ-induced STAT1 serine-phosphorylation and MUC4 expression in pancreatic cancer cells. Co-author DOI 10.1049/iet-syb.2011.0017↗
  8. Parameter identifiability and sensitivity analysis predict targets for enhancement of STAT1 activity in pancreatic cancer and stellate cells. Co-author DOI 10.1371/journal.pcbi.1002815↗
  9. Studies on mechanisms of interferon-gamma action in pancreatic cancer using a data-driven and model-based approach. Last author DOI 10.1186/1476-4598-10-13↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dietmar Zechner · 5 shared papers, 2018–2024 · strength 0.77
  2. Georg Fuellen · 3 shared papers, 2020–2024 · strength 0.47
  3. Hugo Murua Escobar · 3 shared papers, 2020–2023 · strength 0.38
  4. Denis Revskij · 2 shared papers, 2023–2024 · strength 0.38
  5. Olaf Wolkenhauer A · 5 shared papers, 2011–2023 · strength 0.35
  6. Brigitte Vollmar · 2 shared papers, 2018–2024 · strength 0.26
  7. Simone Kumstel · 2 shared papers, 2018–2024 · strength 0.26
  8. Jakob Brandstetter · 1 shared paper, 2024 · strength 0.18
  9. Tim Schreiber · 1 shared paper, 2024 · strength 0.18
  10. Falko Lange · 3 shared papers, 2011–2020 · strength 0.16
  11. Yixuan Ma · 1 shared paper, 2022 · strength 0.14
  12. Frank Ulrich Weiß · 1 shared paper, 2022 · strength 0.14
  13. Benjamin Schulz · 1 shared paper, 2022 · strength 0.14
  14. Markus M. Lerch · 1 shared paper, 2022 · strength 0.14
  15. Katja Rateitschak · 3 shared papers, 2011–2012 · strength 0.11
  16. Larissa Henze · 1 shared paper, 2020 · strength 0.09
  17. Daniel H. Palmer · 1 shared paper, 2020 · strength 0.09
  18. Edgar Heinz Uwe Wendt · 1 shared paper, 2018 · strength 0.08
  19. Maria Schönrogge · 1 shared paper, 2018 · strength 0.08
  20. Xianbin Zhang · 1 shared paper, 2018 · strength 0.08
  21. Christina Kossow · 1 shared paper, 2012 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.